August 2003

Dar Al Dawa Development & Investment Co. Ltd. (DAD) maintains number one ranking in the Jordan pharmaceutical market for the fifth consecutive year

For the fifth consecutive year, Dar Al Dawa has ranked number one in the IMS statistics among all working companies in Jordan. Dar Al Dawa has not only maintained an outstanding position in an extremely competitive market, but also achieved a sustainable increase in its overall sales and profits.

According to a study conducted by Atlas Investment Group, Dar Al Dawa’s performance this year is better than last year, and its earnings before tax are expected to grow up to 7.4 million Jordanian Dinars compared to 6.9 million Jordanian Dinars in the year 2002. The study also concludes that Dar Al Dawa’s EU GMP certificate has enabled the company to register several products in many European countries, which will have a direct impact on its sales and profits in the coming years.

As for Dar Al Dawa’s investment plans and on-going projects, the pharmaceutical plant in Algeria has achieved profits in its first operating year, and the under-construction plant in Libya is expected to operate by next year. The Libyan project is expected to be extremely profitable and is expected to start making profit in its second year.

>> FULL TEXT OF ARTICLE IN ARABIC

back to news archives